dezamizumab

also known as GSK2398852 · Anti - sap mab

Monoclonal antibody targets APCS via inhibition

Developed for: amyloidosis
Investigated by: GlaxoSmithKline · Heart Hospital · Imperial College London · Quintiles, Inc. · Royal Free Hospital NHS Foundation Trust

today NCT03044353 · Ph 2 NCT01777243 · Ph 1

201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT01777243	May 2013 → Dec 2015	amyloidosis	GlaxoSmithKline	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT03044353	Jul 2017 → Jan 2019	amyloidosis	GlaxoSmithKline	Terminated	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT03417830 Background	Apr → Jul 2018	amyloidosis	GlaxoSmithKline	Terminated	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	dezamizumab	“This residual SAP is a specific target for dezamizumab, a fully humanized monoclonal IgG1 anti-SAP antibody that triggers immunotherapeutic clearance of amyloid.” PMID 29298867 ↗ Jan 2018
Known as	Anti - sap mab	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297966 ↗
Known as	GSK2398852	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03044353 ↗ 1 NCT03417830 ↗
Action	Inhibit	“Serum amyloid P-component inhibitor” CHEMBL4297966 ↗
Modality	Monoclonal antibody	“dezamizumab, a fully humanized monoclonal IgG1 anti-SAP antibody” PMID 29298867 ↗ Jan 2018 1 CHEMBL4297966 ↗
Route	Intravenous	“Subjects will be administered up to 490 mg of GSK2398852, IV.” NCT03417830 ↗
Target	APCS	“Serum amyloid P-component inhibitor” CHEMBL4297966 ↗